CRO(위약품 위탁 생산 기관) 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of Contract Manufacturing Organizations (CMO) Market

The global Contract Manufacturing Organizations (CMO) market plays a vital role in the pharmaceutical and biotechnology supply chain by enabling companies to outsource drug manufacturing activities and focus on core functions such as research, development, and commercialization. CMOs offer a wide range of services including API manufacturing, formulation development, stability testing, packaging, and commercial-scale production, while ensuring compliance with strict regulatory standards such as Good Manufacturing Practices (GMP).

According to the report, the global Contract Manufacturing Organizations (CMO) market size was valued at USD 168.24 billion in 2025. The market is projected to grow to USD 181.29 billion in 2026 and further reach USD 341.23 billion by 2034, registering a CAGR of 8.1% during the forecast period. North America dominated the global market in 2025, accounting for 31.90% market share, supported by strong biopharmaceutical manufacturing infrastructure and rising outsourcing of advanced therapies and biologics.

Contract Manufacturing Organizations (CMO) Market Trends

One of the major trends shaping the CMO market is the increasing adoption of digitization and automation in manufacturing processes. CMOs are integrating advanced digital technologies, artificial intelligence, and automated production systems to enhance efficiency, improve quality control, and reduce operational risks.

The shift toward digitalized and automated aseptic manufacturing is gaining momentum, as it enables paperless operations, improved traceability, and faster identification of quality deviations. This trend is strengthening compliance with regulatory standards while improving overall equipment effectiveness (OEE). Additionally, CMOs are increasingly offering end-to-end manufacturing solutions to meet the growing complexity of modern drug development.

Market Growth Factors

The rising outsourcing of biologics and biosimilars manufacturing is a key driver of the Contract Manufacturing Organizations (CMO) market growth. The increasing global burden of chronic diseases such as cancer, diabetes, and neurological disorders has accelerated the demand for complex biologics, which require specialized manufacturing expertise and infrastructure.

Pharmaceutical companies are increasingly partnering with CMOs to manufacture biologics and biosimilars in a cost-effective and scalable manner. Moreover, the growing focus on personalized medicine and gene therapies is creating new opportunities for CMOs with advanced capabilities.

Another major growth factor is the increasing investment by CMOs in expanding their drug manufacturing capacity. To meet rising global demand, CMOs are investing heavily in new facilities, capacity expansion, continuous manufacturing processes, and advanced analytical technologies. These investments enable CMOs to offer integrated services across the drug lifecycle, driving long-term market growth.

Restraining Factors

Despite strong growth prospects, the market faces certain challenges. High costs associated with establishing and expanding pharmaceutical manufacturing facilities act as a major restraint. Building a new production facility requires substantial capital investment, long timelines, and strict regulatory approvals.

Additionally, pharmaceutical companies may hesitate to fully rely on CMOs for critical manufacturing operations due to concerns related to product quality, data security, and supply chain dependency. These factors can limit the entry of new players and restrict market expansion in certain regions.

Contract Manufacturing Organizations (CMO) Market Segmentation Analysis

Based on service, the market is segmented into API manufacturing, finished product manufacturing, and packaging. The API manufacturing segment dominated the market with a 54.28% share in 2026, driven by the increasing outsourcing of API production to achieve cost efficiency and operational flexibility.

The finished product segment held the second-largest share, supported by growing demand for solid dosage forms and injectables, particularly in emerging markets. The packaging segment accounted for a moderate share, as CMOs increasingly provide integrated packaging solutions to ensure timely product delivery.

Regional Insights

North America remained the leading region, with a market value of USD 57.45 billion in 2026, driven by strong investments in biologics manufacturing and strategic collaborations. Europe accounted for a significant market share in 2026, supported by the presence of major CMOs and expansion of API production facilities.

Asia Pacific emerged as the fastest-growing region due to improving healthcare infrastructure, rising pharmaceutical exports, and increasing number of domestic drug manufacturers in countries such as China, Japan, and India.

Key Industry Players

The market is highly fragmented, with key players including Lonza, Catalent, Inc., Thermo Fisher Scientific Inc., Samsung Biologics, and WuXi Biologics. These companies focus on expanding manufacturing capacities, forming strategic partnerships, and enhancing service offerings to strengthen their global presence.

Conclusion

The global Contract Manufacturing Organizations (CMO) market is set to experience sustained growth through 2034, driven by increasing outsourcing of pharmaceutical manufacturing, rising demand for biologics and biosimilars, and continuous investments in advanced manufacturing technologies. While high capital requirements and regulatory complexities pose challenges, expanding healthcare needs, technological advancements, and strategic collaborations are expected to support long-term market expansion and maintain positive growth momentum over the forecast period.

Segmentation By Service

• API Manufacturing
• Finished Product
  • Solid Dosage Forms
  • Injectables
  • Others
• Packaging

By Region

• North America (By Service and Country)
  • U.S.
  • Canada
• Europe (By Service and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Service and Country/Sub-region)
  • India
  • China
  • Japan
  • Australia
  • Rest of Asia Pacific
• Rest of the World (By Service)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Contract Manufacturing Organizations (CMO) Market
• 4.2. Overview of Regulatory Scenario, By Key Countries/Region
• 4.3. Key Industry Developments Mergers, Acquisitions, Partnerships, etc.
• 4.4. Impact of COVID-19 on the Market

5. Global Contract Manufacturing Organizations (CMO) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Service
  • 5.1.1. API Manufacturing
  • 5.1.2. Finished Product
    • 5.1.2.1. Solid Dosage Forms
    • 5.1.2.2. Injectables
    • 5.1.2.3. Others
  • 5.1.3. Packaging
• 5.2. Market Analysis, Insights and Forecast - By Region
  • 5.2.1. North America
  • 5.2.2. Europe
  • 5.2.3. Asia Pacific
  • 5.2.4. Rest of the World

6. North America Contract Manufacturing Organizations (CMO) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Service
  • 6.1.1. API Manufacturing
  • 6.1.2. Finished Product
    • 6.1.2.1. Solid Dosage Forms
    • 6.1.2.2. Injectables
    • 6.1.2.3. Others
  • 6.1.3. Packaging
• 6.2. Market Analysis, Insights and Forecast - By Country
  • 6.2.1. U.S.
  • 6.2.2. Canada

7. Europe Contract Manufacturing Organizations (CMO) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Service
  • 7.1.1. API Manufacturing
  • 7.1.2. Finished Product
    • 7.1.2.1. Solid Dosage Forms
    • 7.1.2.2. Injectables
    • 7.1.2.3. Others
  • 7.1.3. Packaging
• 7.2. Market Analysis, Insights and Forecast - By Countries/Sub-region
  • 7.2.1. Germany
  • 7.2.2. France
  • 7.2.3. U.K.
  • 7.2.4. Italy
  • 7.2.5. Spain
  • 7.2.6. Scandinavia
  • 7.2.7. Rest of the Europe

8. Asia Pacific Contract Manufacturing Organizations (CMO) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Service
  • 8.1.1. API Manufacturing
  • 8.1.2. Finished Product
    • 8.1.2.1. Solid Dosage Forms
    • 8.1.2.2. Injectables
    • 8.1.2.3. Others
  • 8.1.3. Packaging
• 8.2. Market Analysis, Insights and Forecast - By Countries/Sub-region
  • 8.2.1. China
  • 8.2.2. Japan
  • 8.2.3. India
  • 8.2.4. Australia
  • 8.2.5. Rest of Asia Pacific

9. Rest of the World Contract Manufacturing Organizations (CMO) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Service
  • 9.1.1. API Manufacturing
  • 9.1.2. Finished Product
    • 9.1.2.1. Solid Dosage Forms
    • 9.1.2.2. Injectables
    • 9.1.2.3. Others
  • 9.1.3. Packaging

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles (Overview, Services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 10.2.1. Boehringer Ingelheim International GmbH
    • 10.2.1.1. Overview
    • 10.2.1.2. Services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Almac Group
    • 10.2.2.1. Overview
    • 10.2.2.2. Services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Recipharm AB
    • 10.2.3.1. Overview
    • 10.2.3.2. Services
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Dr. Reddy's Laboratories Ltd.
    • 10.2.4.1. Overview
    • 10.2.4.2. Services
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. FAMAR Health Care Services
    • 10.2.5.1. Overview
    • 10.2.5.2. Services
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Lonza
    • 10.2.6.1. Overview
    • 10.2.6.2. Services
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Vetter Pharma-Fertigung GmbH & Co. KG
    • 10.2.7.1. Overview
    • 10.2.7.2. Services
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Jubilant Pharmova Limited
    • 10.2.8.1. Overview
    • 10.2.8.2. Services
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Catalent Inc.
    • 10.2.9.1. Overview
    • 10.2.9.2. Services
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)